BioSpace News Archive

CASI Pharmaceuticals, Inc. reported financial results for the second quarter and six months ended June 30, 2019 and provided a review of recent accomplishments and anticipated milestones.

Quanterix Corporation (Nasdaq: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the pricing of its previously announced underwritten public offering of 2,376,238 shares of its common stock at a public offering price of $25.25 per share.

Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in late-stage clinical trials for the treatment of patients with urological diseases, today reported financial results for the second quarter 2019 and recent corporate highlights.

Ardelyx, Inc. (NASDAQ: ARDX), a specialized biopharmaceutical company focused on developing first-in-class medicines to improve treatment choices for people with cardiorenal diseases, today reported business highlights and financial results for the second quarter ended June 30, 2019.

Akebia Therapeutics, Inc. announced that John P. Butler, President and Chief Executive Officer of Akebia, will participate in the following investor conferences

Bioenergy DevCo, a leading global developer of anaerobic digestion facilities that create renewable energy and healthy soil products, announced today that it has acquired BTS Biogas, which will operate as an affiliate and enable new operation and expansion of anaerobic digestion in North America.

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China National Medical Products Administration (NMPA) has approved Biktarvy® (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg, BIC/FTC/TAF), a once-daily single tablet regimen (STR) for the treatment of HIV-1 infection.

TAGRISSO is the only medicine demonstrating statistically-significant overall survival benefit in this setting. Also increased the time patients with central nervous system metastases lived without disease progression

CannTrust Holdings Inc. (“CannTrust” or the “Company”, TSX: TRST, NYSE: CTST) today announced that the Company’s independent auditor, KPMG LLP, Chartered Professional Accountants (“KPMG”), has informed the Company that effective August 8, 2019, it is withdrawing its report dated March 27, 2019

Diplomat Pharmacy, Inc. (NYSE: DPLO) today announced that its Board of Directors is reviewing strategic alternatives.